Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 6, 2023, scPharmaceuticals Inc. (the "Company") held its Annual Meeting of Stockholders. A total of 20,462,341 shares of common stock were present online or represented by proxy at the meeting, representing approximately 57.2 percent of the Company's outstanding common stock as of the April 11, 2023 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023.

Proposal 1 - Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified or until their earlier resignation or removal.


          NOMINEE                 FOR       WITHHELD   Broker Non-Votes

John H. Tucker 15,928,864 68,923 4,464,554

Jack A. Khattar 15,785,416 212,371 4,464,554 Klaus Veitinger, M.D., Ph.D. 15,164,483 833,304 4,464,554

Proposal 2 - Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.



   FOR       AGAINST   ABSTAINED   Broker Non-Votes
20,425,686   18,204     18,451            0

Proposal 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.

FOR AGAINST ABSTAINED Broker Non-Votes 15,898,880 79,114 19,793 4,464,554

Proposal 4 - Approval, on an advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers.



  1 YEAR      2 YEARS    3 YEARS   ABSTAINED   Broker Non-Votes
10,278,946   5,626,332   52,171     40,338        4,464,554

Based on the foregoing votes, John H. Tucker, Jack A. Khattar and Klaus Veitinger, M.D., Ph.D. were elected as Class III Directors, Proposals 2 and 3 were approved and the Company's stockholders recommended that future stockholder advisory votes on the compensation of the Company's named executive officers be held every year.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses